MITA USA Founder Demitri Downing was recently featured in The Washington Times as an industry source discussing Cannabinoid Hyperemesis Syndrome (CHS), a condition associated with chronic cannabis use that can cause recurring episodes of severe nausea, vomiting, and abdominal pain. The article, published August 26, examines growing attention around the condition and what increasing awareness may mean for consumers, healthcare providers, and the cannabis industry.
The conversation followed a new JAMA Insights report examining CHS, its symptoms, complications, and treatment. According to the material provided to Downing, CHS can result in significant health consequences, including dehydration, acute kidney injury, electrolyte imbalances, emergency room visits, and hospitalization. Long-term management centers on stopping cannabis use, alongside supportive treatment when necessary.
Downing emphasized that CHS is a legitimate health issue and one the cannabis industry should take seriously.
In his comments to The Washington Times, he noted that severe cases can involve dehydration, kidney injury, electrolyte problems, and hospitalization, making it important not to dismiss the condition. At the same time, he argued that conversations around cannabis-related health risks should remain grounded in perspective rather than becoming sensationalized.
That distinction is especially important as cannabis becomes more widely available and more openly studied. Increased legalization has created greater opportunities for researchers and medical professionals to examine both the benefits and potential risks associated with cannabis use.
Downing pointed to several factors that may be contributing to the increased recognition of CHS: more people consuming cannabis, access to higher-potency products, heavy patterns of use among some consumers, and physicians becoming better at recognizing the condition.
CHS itself is not new. Downing noted that it was formally described in Australia in 2004 among heavy cannabis users experiencing recurring vomiting and abdominal pain, with symptoms sometimes temporarily relieved by hot showers. Symptoms may resolve after stopping cannabis and return if cannabis use resumes.
As awareness continues to grow, better recognition may naturally lead to more diagnoses.
When asked which cannabis products may present the greatest concern, Downing pointed particularly to high-potency concentrates, while also emphasizing that the current evidence does not support reducing CHS risk to one specific product category.
Dose, frequency of consumption, duration of use, and individual biology can all play a role.
This is an increasingly relevant conversation for a maturing cannabis industry. Innovation has created more sophisticated and potent products, but greater product choice also reinforces the need for responsible consumption, consumer education, and honest conversations about risk.
For Downing, acknowledging CHS does not mean accepting exaggerated narratives about cannabis. Instead, it represents an opportunity for the industry to demonstrate maturity.
He argued that cannabis companies and advocates should recognize legitimate risks rather than treating cannabis as exempt from the biological consequences associated with drug use. At the same time, he cautioned against portraying a condition affecting a subset of heavy users as evidence that cannabis is uniquely dangerous.
That balance — acknowledging risks while communicating them responsibly and in context — is an important part of building a sustainable cannabis industry.
As research continues to expand, manufacturers, brands, regulators, healthcare professionals, and consumers will all benefit from more accurate information about cannabis use, dosage, potency, and potential side effects.
Demitri Downing’s comments were featured in The Washington Times article:
“Study warns marijuana users suffering ‘scream-vomiting’ to quit the drug.”
Read the full article in The Washington Times.